Key result
Pregnancy GERD treatment prioritizes antacids and ranitidine, reserving PPIs for non-responsive cases after the first trimester.
Provides a review of safe medical treatment options for GERD during pregnancy and lactation, highlighting ranitidine as preferred and cautioning against omeprazole.
May inform stepwise GERD therapy choices in pregnancy; leaves open need for prospective randomized safety data.
Gastroesophageal reflux disease (GERD) is frequently seen during pregnancy. In the medical treatment of pregnant women with GERD, alginic acid and sucralfate can be used. Calcium- and magnesium-based antacids can also be used, particularly for patients with preeclampsia. In particular, ranitidine -a histamine-2 receptor blocker- is preferred. In the case of non-responsiveness to the abovementioned treatments, proton pump inhibitors (PPIs), except omeprazole, can be given considering the benefit-harm ratio for the mother and fetus after the first trimester. In cases with GERD during the lactation period, drugs having minimum systemic absorption, such as sucralfate and alginic acid, are preferable but there is no data. Cite this article as: Dağlı Ü, Kalkan İH. Treatment of reflux disease during pregnancy and lactation.
No takes yet. Share an insight, caveat, or question.
Dağlı et al. (2017) conducted a review in Gastroesophageal reflux disease (GERD). Medical treatment (alginic acid, sucralfate, antacids, ranitidine, PPIs) was evaluated. Medical treatment of GERD during pregnancy involves alginic acid, sucralfate, antacids, and ranitidine, with PPIs reserved for non-responsive cases after the first trimester.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: